Does tirzepatide work by changing metabolism or appetite? What a mechanism trial shows

A common question about medical weight loss is whether a drug such as tirzepatide works by changing metabolism or by reducing how much a person eats, and a 2025 trial addressed this directly ^[1]. Tirzepatide is an agonist of the receptors for glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), and it produced significant body weight reduction in phase 3 clinical trials ^[1]. The 2025 paper in Cell Metabolism paired a mouse study with a phase 1 randomized, placebo-controlled trial in people with obesity (NCT04081337), examining calorie intake, energy expenditure and macronutrient utilization ^[1]. In humans, the reported effects were on appetite, test-meal intake and fat oxidation rather than on metabolic adaptation ^[1].

Three terms that frame the question

• In the study's framing, metabolic adaptation is the drop in energy expenditure that occurs under calorie restriction, and the researchers tested whether tirzepatide attenuates that drop ^[1].
• Fat oxidation is the study's outcome for how much fat the body uses, reported as part of macronutrient utilization; in mice, a decrease in the respiratory exchange ratio was taken to indicate increased fat oxidation, and the abstract does not state how it was measured in people ^[1].
• Macronutrients are the nutrients the body needs in relatively large amounts: protein, fat and carbohydrates ^[5].

What happened in mice

In calorie-restricted, obese mice, chronic tirzepatide treatment reduced the drop in energy expenditure seen in two control groups, vehicle-treated and pair-fed mice, which the authors interpreted as attenuation of metabolic adaptation ^[1]. The respiratory exchange ratio also decreased in treated mice, which the authors interpreted as increased fat oxidation ^[1]. Taken alone, the mouse data would point toward tirzepatide limiting the fall in energy expenditure during calorie restriction ^[1].

What happened in people

In the phase 1 clinical trial, tirzepatide appeared to have no impact on metabolic adaptation compared with placebo ^[1]. It did lead to increased fat oxidation and to reductions in appetite and in calorie intake during an ad libitum test meal, compared with placebo ^[1]. The mouse finding on energy expenditure therefore did not carry over to the human trial, while the finding on fat oxidation did ^[1]. The authors describe the work as the first study to provide insight into tirzepatide's mechanisms of weight loss with respect to calorie intake, energy expenditure and macronutrient utilization ^[1].

The abstract does not report the number of participants, the doses, the treatment duration or effect sizes for any human outcome, so the size of these effects cannot be judged from it ^[1].

Background on protein

Consumer health references provide background on protein, one of the three macronutrients ^[4][5]. Dietary protein is broken down into amino acids, which the body uses to build new proteins, and protein synthesis happens constantly because proteins break down over time ^[4]. Unlike fat and carbohydrates, the body does not store protein, so it has no reservoir to draw on when it needs a new supply ^[5]. How much protein a person needs depends on factors including age, activity level, body weight and daily calorie needs ^[4].

WebMD reports on a review of published studies on high-protein diets, discussed by a Harvard nutrition researcher at a symposium, in which clinical studies consistently showed increased satiety and decreased hunger compared with high-fat or high-carbohydrate diets ^[5]. According to that account, most but not all of the reviewed studies showed that people on high-protein diets took in about 10% less energy, roughly 200 calories, per day, and weight loss averaged about 4.5 lbs more than on other diets after six months, with effectiveness declining after that point ^[5]. This is a secondary report of unspecified studies and supports background only, not a measured effect ^[5].

Other routes to eating less

A dietary approach without a drug produced greater short-term weight loss than two glucose-lowering drugs in a randomized setting ^[3]. The EARLY trial, an open-label, multicentre randomized trial across 9 centres in China, assigned 405 adults with overweight or obesity and early type 2 diabetes to metformin, empagliflozin or a 5:2 meal replacement plan, meaning 2 nonconsecutive fasting days and 5 days of habitual intake per week ^[3]. At week 16, the 5:2 group lost a mean of 9.7 kg, compared with 5.5 kg on metformin and 5.8 kg on empagliflozin ^[3]. The 5:2 group also had the largest reduction in hemoglobin A1c (HbA1c), the trial's primary end point and a measure of glycemic control: -1.9%, against -1.6% with metformin (adjusted difference -0.3%, 95% CI -0.4% to -0.1%) and -1.5% with empagliflozin (adjusted difference -0.4%, 95% CI -0.6% to -0.2%) ^[3].

Other investigational drugs act on different receptors to reduce intake ^[2]. Eloralintide is an amylin analog and amylin receptor agonist, and it dose-dependently reduced food intake and body weight, primarily through fat mass loss, in diet-induced obese rats ^[2]. In a phase 1 randomized, placebo-controlled trial of 48 healthy participants with a mean body mass index of 27.5 kg/m2, single doses of 4 mg and 12 mg were followed by week-4 mean weight changes of -2.5% (p < 0.01) and -4.4% (p < 0.001), against +0.6% with placebo ^[2]. Nine participants in the eloralintide cohorts reported 16 adverse events, most of them mild ^[2].

Limitations

• The tirzepatide findings come from an abstract that gives no sample size, dose, duration or effect sizes, so the strength of the human results cannot be judged from it ^[1].
• The human trial was phase 1 and mechanistic, and the mouse results on metabolic adaptation did not reproduce in people ^[1].
• The reduction in human calorie intake was measured during an ad libitum test meal, not reported as a change in habitual daily intake ^[1].
• EARLY was open-label, enrolled Chinese adults with early type 2 diabetes, ran 16 weeks with an 8-week follow-up, and 332 of 405 participants completed treatment ^[3].
• The eloralintide human data reflect single doses in healthy participants followed to week 4 ^[2].
• The protein material comes from consumer health references and supports background only ^[4][5].